Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.

Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P.

J Am Chem Soc. 2008 May 7;130(18):6025-39. doi: 10.1021/ja800834y. Epub 2008 Apr 8.

PMID:
18393503
2.

Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model.

Morelli JN, Runge VM, Williams JM, Beissner RS, Tweedle M.

Invest Radiol. 2011 Mar;46(3):169-77. doi: 10.1097/RLI.0b013e3181f7a0b0.

PMID:
21150792
3.

In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent.

Botnar RM, Buecker A, Wiethoff AJ, Parsons EC Jr, Katoh M, Katsimaglis G, Weisskoff RM, Lauffer RB, Graham PB, Gunther RW, Manning WJ, Spuentrup E.

Circulation. 2004 Sep 14;110(11):1463-6. Epub 2004 Jul 6.

4.

Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent.

Spuentrup E, Katoh M, Buecker A, Fausten B, Wiethoff AJ, Wildberger JE, Haage P, Parsons EC Jr, Botnar RM, Graham PB, Vettelschoss M, Günther RW.

Invest Radiol. 2007 Aug;42(8):586-95.

PMID:
17620942
5.

Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility.

Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, Hartmann MG, Caravan P, Parsons EC Jr.

Invest Radiol. 2009 Nov;44(11):697-704. doi: 10.1097/RLI.0b013e3181b092a7.

PMID:
19809344
6.

Peptide optimization and conjugation strategies in the development of molecularly targeted magnetic resonance imaging contrast agents.

Kolodziej AF, Zhang Z, Overoye-Chan K, Jacques V, Caravan P.

Methods Mol Biol. 2014;1088:185-211. doi: 10.1007/978-1-62703-673-3_13.

PMID:
24146405
7.

MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients.

Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, Ozgun M, Nagel E, Vymazal J, Graham PB, Günther RW, Maintz D.

Eur Radiol. 2008 Sep;18(9):1995-2005. doi: 10.1007/s00330-008-0965-2. Epub 2008 Apr 19.

PMID:
18425519
8.

Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent.

Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA.

Circulation. 2005 Sep 13;112(11):1594-600. Epub 2005 Sep 6.

9.

Molecular MRI of intracranial thrombus in a rat ischemic stroke model.

Uppal R, Ay I, Dai G, Kim YR, Sorensen AG, Caravan P.

Stroke. 2010 Jun;41(6):1271-7. doi: 10.1161/STROKEAHA.109.575662. Epub 2010 Apr 15.

10.

Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrin-targeted contrast agent: experimental study in a swine model.

Spuentrup E, Katoh M, Wiethoff AJ, Buecker A, Botnar RM, Parsons EC, Guenther RW.

Rofo. 2007 Nov;179(11):1166-73.

PMID:
17948194
11.

Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis.

Andia ME, Saha P, Jenkins J, Modarai B, Wiethoff AJ, Phinikaridou A, Grover SP, Patel AS, Schaeffter T, Smith A, Botnar RM.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1193-8. doi: 10.1161/ATVBAHA.113.302931. Epub 2014 Apr 10.

12.

Molecular imaging of fibrin in a breast cancer xenograft mouse model.

Uppal R, Medarova Z, Farrar CT, Dai G, Moore A, Caravan P.

Invest Radiol. 2012 Oct;47(10):553-8. doi: 10.1097/RLI.0b013e31825dddfb.

13.

Eu-chelate anti-fibrin antibody-conjugated perfluorocarbon nanoparticles .

Zhang H.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Jan 17 [updated 2008 Feb 20].

14.

A Manganese Alternative to Gadolinium for MRI Contrast.

Gale EM, Atanasova IP, Blasi F, Ay I, Caravan P.

J Am Chem Soc. 2015 Dec 16;137(49):15548-57. doi: 10.1021/jacs.5b10748. Epub 2015 Dec 4.

15.

Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent.

Spuentrup E, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, Mahnken AH, Günther RW, Buecker A.

Am J Respir Crit Care Med. 2005 Aug 15;172(4):494-500. Epub 2005 Jun 3.

PMID:
15937292
16.

Preparation and in vitro evaluation of GdDOTA-(BOM)4; a novel angiographic MRI contrast agent.

Hovland R, Aasen AJ, Klaveness J.

Org Biomol Chem. 2003 May 21;1(10):1707-10.

PMID:
12926358
17.

Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent.

Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ.

Inorg Chem. 2007 Aug 6;46(16):6632-9. Epub 2007 Jul 11.

PMID:
17625839
18.

Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent.

Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, Weisskoff RM, Graham PB, Manning WJ, Günther RW.

Circulation. 2005 Mar 22;111(11):1377-82. Epub 2005 Feb 28.

19.

Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.

Caravan P.

Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p.

PMID:
19222207
20.

The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents.

McMurry TJ, Parmelee DJ, Sajiki H, Scott DM, Ouellet HS, Walovitch RC, Tyeklár Z, Dumas S, Bernard P, Nadler S, Midelfort K, Greenfield M, Troughton J, Lauffer RB.

J Med Chem. 2002 Aug 1;45(16):3465-74.

PMID:
12139457

Supplemental Content

Support Center